Treatment of Bacterial Vaginosis: A Multicenter, Double-Blind, Double-Dummy, Randomised Phase III Study Comparing Secnidazole and Metronidazole

Table 2

Overall therapeutic success at D28 (primary efficacy endpoint).

	Population
	ITT	mITT	PP
Secnidazole	58.3%	60.1%	63.4%
	(169/290)	(146/243)	(137/216)
Metronidazole	57.8%	59.5%	62.9%
	(166/287)	(141/237)	(127/202)
95% CI Secnidazole-Metronidazole	[−0.076; 0.085]	[−0.082; 0.094]	[−0.087; 0.098]

NS: not significant.